Envoy Medical, Inc. (COCH) - Form 8-K Summary
Business Context and Reporting Period
Envoy Medical, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on March 23, 2026. The filing serves to announce the Company's financial results for its fourth fiscal quarter and the full fiscal year ended December 31, 2025. The Company's Class A Common Stock and Redeemable Warrants trade on The Nasdaq Stock Market LLC under the symbols COCH and COCHW, respectively.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K acts as a notification that a press release containing these details has been issued. The specific financial data is contained in Exhibit 99.1 (Press Release dated March 23, 2026), which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus prior periods within the text provided. It solely references the issuance of the press release regarding the Q4 and full-year 2025 results. Any material changes would be detailed in the attached Exhibit 99.1.
Guidance, Outlook, and Risks
The provided text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These elements are expected to be found in the referenced press release (Exhibit 99.1). The filing notes that the information in Item 2.02 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q4 and full-year 2025 revenue, net income, and cash flow figures.
- Verify the Company's liquidity position and debt obligations as detailed in the press release.
- Check for any updated financial guidance or strategic outlook provided in the March 23, 2026 announcement.
- Confirm the status of the Interim Chief Financial Officer, Robert Potashnick, who signed the report.